PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026Diabetes Therapy2 citationsOpen Access

Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates

IRImran Rashid RangrazeMEMohamed El-TananiAJAndrej Janež

Key Result

Tirzepatide treatment for more than 1 year achieved a median weight reduction of 22.6% compared to 8.1% with short-term treatment in adults with obesity.

Key Points

  • This research aims to evaluate the effectiveness of Tirzepatide on cardio-metabolic-kidney syndrome outcomes in individuals with obesity over a two-year period.
  • Analyzed real-world evidence from patients receiving Tirzepatide treatment
  • Examined cumulative benefits across CKM syndrome outcomes
  • Focused on adherence challenges during treatment
  • Tirzepatide demonstrated greater cumulative benefits in CKM syndrome outcomes during the second treatment year.
  • Highlighting the critical role of adherence to maximize treatment effectiveness.

Study Design

Type

Cohort (n=100)

Multicenter

No

Structured PICO

Does long-term tirzepatide treatment improve weight loss and cardio-metabolic-kidney outcomes compared to short-term treatment in adults with obesity without T2DM?

P
Population
100 adults with obesity (BMI ≥ 30 kg/m2) without type 2 diabetes mellitus, mean age 37.6 years, 75% male, treated in a real-world clinical setting in the United Arab Emirates.
I
Intervention
Tirzepatide initiated at 2.5 mg once weekly and titrated up to a maximum of 15 mg weekly, administered long-term (> 1 year, mean duration 1.5 years).
C
Comparator
Tirzepatide administered short-term (≤ 1 year, mean duration 0.74 years).
O
Outcome
Percentage change in body weight from baseline to follow-up.surrogate

Real-world evidence shows that tirzepatide treatment persisting beyond one year provides substantially greater weight loss and cardio-metabolic-kidney benefits compared to shorter-term treatment in adults with obesity.

Main Result

Absolute Event Rate: -22.6% vs -8.1%

p-value: p=<0.001

Limitations

  • Observational design may be subject to selection bias
  • Modest sample size
  • Single-center study
  • Adherence was not systematically monitored
  • Incomplete documentation of reasons for treatment discontinuation in electronic medical records

Abstract

Tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year, highlighting the need to overcome adherence barriers in real-world settings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rangraze et al. (2026) conducted a cohort in Obesity without type 2 diabetes mellitus (n=100). Tirzepatide vs. Short-term treatment (≤ 1 year) was evaluated on Percentage change in body weight (p=<0.001). Tirzepatide treatment for more than 1 year achieved a median weight reduction of 22.6% compared to 8.1% with short-term treatment in adults with obesity.

synapsesocial.com/papers/69edad4b4a46254e215b4e59https://doi.org/10.1007/s13300-026-01868-2
Ask AI
Helpful
Bookmark
Share
View Full Paper